PubMed Health⌕ Search

Biomedical subjects

C L McLaughlin

Publications and source records attributed to C L McLaughlin.

At least 37 records · Page 2Linked to original sources
PubMed1986

Changes in brain met-enkephalin concentrations with peripheral CCK injections in Zucker rats.

There is increasing evidence that peptides in the brain are important in the control of food intake. Administration of opioid and CCK peptides have elicited hunger and satiety, respectively. To evaluate the interaction of these peptides and their role in the central nervous system, concentrations of met-enkephalin were measured in the hypothalamus of rats following peripheral administration of CCK; in addition, effects of feeding and fasting and obesity were studied. In CCK- vs. saline-injected rats met-enkephalin concentrations were decreased in the paraventricular nucleus (PVN), suprachiasmatic nucleus (SC), supraoptic nucleus (SON), dorsomedial hypothalamus (DMH) and ventromedial hypothalamus (VMH). In fed compared with fasted rats met-enkephalin concentrations were higher in the anterior hypothalamus (AH) and lower in the SC; in obese compared with lean rats, concentrations were higher in the AH, PVN, SC, SON, DMH, lateral hypothalamus and VMH. These results show that peripheral injections of CCK can decrease concentrations of met-enkephalin in the brain and suggest a mechanism by which these peptides may interact to influence behavior. In addition, the findings support the hypothesis that the hyperphagia which is typical of obese rats may be due to increased concentrations of met-enkephalin.

Animals↗
PubMed1986

Role of glucagon in the control of food intake in Zucker obese and lean rats.

Although there is strong evidence for glucagon's role in the control of food intake, the essentiality of this role remains in question. In several experiments the feeding responses to glucagon and glucagon antisera were investigated in both Zucker and Sprague-Dawley rats. Intraperitoneal injection of 400 micrograms/kg glucagon decreased 30-min food intake 18% (p less than 0.01) in Zucker lean rats and increased 30-min food intake 16% (NS) in Zucker obese rats, suggesting obese rats are less sensitive. In Sprague-Dawley rats the same dose decreased first meal size 28% (p less than 0.01), indicating that they were more sensitive than Zucker lean rats. Intraperitoneal injection of 400 micrograms/kg glucagon increased plasma glucagon concentrations in the vena cava and the tail vein 150-fold and 10-fold, thus, superphysiological doses may be required to elicit satiety. In contrast, administration of a glucagon antisera increased food intake of Zucker rats for up to 6 hr and increased meal size for 5 hr. The findings suggest that glucagon's role in control of food intake in Zucker obese and lean rats is similar, but the superphysiological glucagon changes which occur with exogenous administration indicate that glucagon may only indirectly elicit satiety.

Animals↗
PubMed1986

Role of cholecystokinin and opioid peptides in control of food intake.

Of the many factors that influence food intake, there is strong evidence that opioid and CCK peptides, which stimulate feeding and elicit satiety, respectively, are important components that may act in concert to regulate energy balance. Cholecystokinin peptides have been isolated in both the brain and gastrointestinal tract, and changes in concentration in the brain and in plasma have been shown to vary with feeding. Peripherally injected CCK has been shown to elicit satiety in many species, including humans, an effect that may be mediated in the CNS via the vagus. In several species, most notably the sheep, direct injection into the CSF potently decreases food intake. Questions remaining regarding the role of CCK peptides in eliciting satiety include the sites and mechanisms of action. It is unknown whether CCK acts directly on receptors, indirectly on some other parameter, or as a neurotransmitter. Although opioid peptides have also been localized in portions of both the periphery and brain, a specific physiological role for their presence has not yet been determined. Opioid peptides from three families--endorphins, enkephalins, and dynorphins--have been shown to stimulate feeding in various species. They have been active at several opioid receptor types in the CNS, but there is limited evidence to suggest they affect food intake when administered peripherally. In contrast, peripheral injection of opiate antagonists has effectively decreased food intake, an observation that led to the original hypothesis that opioids were involved in the hunger component in the control of food intake and that excess concentrations might be involved in the development of obesity. An increasing body of evidence supports the concept that opioid and CCK peptides may interact to control food intake, but the evidence is more suggestive than conclusive.

Amino Acid Sequence↗
PubMed1986

Influence of nalmefene on energy balance and glucose regulation in Zucker rats.

It has been hypothesized that opioid peptides play a role in the development of obesity. The opiate antagonist naltrexone decreases glucose-stimulated insulin release, while the sensitivity of diabetic rats to naloxone-induced satiety is increased. These findings suggest a possible interaction between glucose concentrations and opiate antagonists in the control of food intake. In three experiments the energy balance and glucose regulatory responses of Zucker obese and lean rats to chronic administration of nalmefene, an opiate antagonist, were measured. Nalmefene, when injected subcutaneously or added to feed for 21 days, decreased food intake and weight gain of obese and lean rats. These responses were more pronounced during the first week of treatment and were greater in obese than lean rats. Nalmefene increased glucose concentrations during day 1 and weeks 1, 2 and 3 only when given subcutaneously. Nalmefene given intragestrically attenuated glucose-stimulated increases in insulin release only in obese rats. Thus, chronic nalmefene administration is not likely to be an effective treatment for obesity or diabetes.

Administration, Oral↗
PubMed1985

Effect of CCK antibodies on food intake and weight gain in Zucker rats.

While exogenous administration of cholecystokinin (CCK) decreases food intake in many species, it has not been demonstrated conclusively that CCK is necessary for satiety to occur. In these experiments the role of CCK in eliciting satiety was further investigated by using endogenously produced and exogenously administered antibodies to CCK which were hypothesized to sequester circulating CCK. In the first experiment Zucker obese (n = 12, 192 +/- 16 g) and lean (n = 12, 152 +/- 11 g) male rats were administered CCK-8 conjugated to bovine serum albumin or bovine serum albumin by subcutaneous administration in Freund's adjuvant. Average percent binding of 125I-gastrin-17 by serum taken 4, 8 and 12 weeks after treatment initiation was increased (19.9 vs. 2.1, p less than 0.001) in rats treated with CCK conjugate than controls, and the increase was greater in lean (27.5 vs. 1.9) than in obese (12.2 vs. 2.2, p less than 0.001) rats. In lean, but not obese rats, average daily food intake and weight gain were increased (9 and 17% p less than 0.04 and p less than 0.02 respectively) in rats with CCK-AB compared with rats with no CCK-AB during the three months. Development of CCK-AB did not affect food intake response to exogenously administered CCK-8 or pancreas weight relative to body weight. In Experiment 2 increased food intakes of obese and lean rats 30 min after intraperitoneal injection of rabbit serum with CCK-AB were greater than those after intraperitoneal injection of rabbit serum without CCK-AB (1.92 vs. 1.41, g, p less than 0.007).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1985

Meal-stimulated increased concentrations of beta-endorphin in the hypothalamus of Zucker obese and lean rats.

Increased opiate peptide concentrations in brain and plasma have been associated with increased feeding. The role of beta-endorphin in the control of food intake and obesity was examined by measuring concentrations in hypothalamus, pituitary and plasma of hungry (6-hr fasted) and satiated (5 min after a meal) Zucker obese and lean rats. beta-Endorphin concentrations (1) in satiated vs. hungry rats were increased in the VMH (90 vs. 79 pg/mg tissue, p less than 0.05) and decreased in the supraoptic nucleus (65 vs. 78 pg/mg tissue, p less than 0.05), (2) in obese vs. lean rats were decreased in the VMH (79 vs. 90 pg/mg tissue, p less than 0.05) and (3) in female vs. male rats were increased in the anterior hypothalamus (123 vs. 59 pg/mg tissue, p less than 0.01) and VMH (90 vs. 79 pg/mg tissue, p less than 0.05). Analysis of a phenotype by feeding condition interaction revealed that obese but not lean rats had higher beta-endorphin concentrations in the satiated vs. hunger condition. However, plasma beta-endorphin concentrations did not differ with feeding condition, phenotype or sex. Intermediate and posterior but not anterior pituitary beta-endorphin concentrations were lower in obese than lean rats. Thus, there is some evidence for a relationship between beta-endorphin concentration and feeding in the hypothalamus, but beta-endorphin concentrations in plasma do not appear to be influenced by feeding condition or obesity.

Animals↗
PubMed1985

Autoimmunization against beta-endorphin increases food intakes and body weights of obese rats.

Opioid peptides in the brain are postulated to mediate the hunger component of the control of food intake and regulation of body weight and concentrations are increased in the pituitaries of genetically obese rodents. However, systemic increases in opioids have been associated with satiety. Thus a chronic decrease in systemic concentrations of the opioid beta-endorphin induced by autoimmunization was predicted to increase food intake and body weight. Zucker obese (n = 20, 568 +/- 13 g) and lean (n = 20, 299 +/- 16 g) rats were autoimmunized against bovine serum albumin (BSA) or BSA conjugated to beta-endorphin (BSA-BE). Eight weeks after immunization serum from BSA-BE rats bound at least 7 times the circulating concentration of beta-endorphin. Food intakes were greater in BSA-BE obese (31.7 vs. 30.4 g/day, p less than 0.001) and lean rats (21.4 vs. 21.0 g/day, p less than 0.007) during weeks 5-8 and only obese rats, weeks 9-12 (31.8 vs. 30.3 g/day, p less than 0.009). Body weight gains were greater for BSA-BE than BSA obese rats during weeks 1-4 (1.34 vs. 0.92 g/day, p less than 0.05) and 9-12 (0.95 vs. 0.43 g/day, p less than 0.01). At 8 weeks the plasma concentrations of "free" beta-endorphin were decreased 78% (34 vs. 154 pmol/l, p less than 0.001) and "total" ("free" plus antibody-bound) beta-endorphin were increased (427 vs. 101 pmol/l, p less than 0.001). These results suggest that systemic concentrations of beta-endorphin may play an important role in the control of food intake and regulation of energy balance.

Animals↗
PubMed1985

Meal-stimulated increased concentrations of CCK in the hypothalamus of Zucker obese and lean rats.

CCK is a putative satiety peptide found to be active when administered peripherally and centrally. Concentrations of CCK have been measured in the brains of fed and fasted animals, but as yet no clear correlation with feeding has been found. In the present experiment rats were sacrificed after a 6-hr fast or 5 min after a meal. Areas of the hypothalamus were removed from these rats and assayed for CCK content. The relationship between obesity and CCK content in specific areas of the brain was also investigated by using Zucker obese and lean rats. In fed rats the CCK concentrations were higher than in fasted rats in the ventromedial hypothalamus (VMH) (56 vs. 42 pg/mg tissue, p less than 0.005), lateral hypothalamus (38 vs. 27 pg/mg, p less than 0.01) and supraoptic nucleus (48 vs. 39 pg/mg, p less than 0.01). In obese rats the concentrations were higher than in lean rats in the VMH (56 vs. 41 pg/mg, p less than 0.003), dorsal medial hypothalamus (37 vs. 30 pg/mg, p less than 0.04) and anterior hypothalamus (61 vs. 37 pg/mg, p less than 0.001). Average concentrations of CCK in all hypothalamic areas were higher in females than males (50 vs. 40 pg/mg, p less than 0.001). Thus, CCK concentrations in specific areas of the hypothalamus increased with feeding, supporting the potential role of CCK in the central nervous system as a satiety peptide. Further, although the concentrations of CCK in obese rats were higher than those in lean rats, the changes in CCK concentration with feeding were the same, showing that obesity is not a consequence of decreased concentrations or concentration changes of CCK in brain.

Animals↗
PubMed1984

Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin.

Administration of cholecystokinin was recently found to attenuate opiate analgesia. In the present study, the role of endogenous cholecystokinin in opiate analgesia was examined. Endogenously released cholecystokinin was sequestered by antibodies to cholecystokinin developed in response to an active immunization procedure. Morphine analgesia was potentiated and prolonged in rats immunized against cholecystokinin. The rate of development of morphine tolerance, however, was not affected by the antibodies. Endogenous cholecystokinin appears to function as a short-term modulator of opiate action.

Animals↗
PubMed1984

Decreased food intakes and body weights in rats immunized against pancreatic glucagon.

Glucagon, a putative satiety peptide, has decreased food intake and antibodies to glucagon have increased food intake when administered acutely. It may be hypothesized if rats were immunized against glucagon, antibodies would chronically sequester glucagon released during meals and food intake and weight gain would increase. Female Zucker obese (n = 16, BW = 160 +/- 5 g) and lean (n = 16, BW = 123 +/- 3 g) rats were immunized against pancreatic glucagon conjugated to BSA (GG-AB) or BSA alone (BSA-AB). Only GG-AB rats developed glucagon antibody titers (p less than 0.01). During a 16 week period average daily food intakes and body weight gains were decreased 5.0 (p less than 0.001) and 9.4% (p less than 0.001) respectively in GG-AB compared with BSA-AB rats. Free glucagon, measured by RIA using a pancreatic glucagon specific antibody, was decreased 60% at 8 weeks (130 vs. 322 pg/ml, p less than 0.001) and 33% at 16 weeks (206 vs. 307 pg/ml, p less than 0.02). However, total pancreatic glucagon (free and antibody-bound) was increased 226% (428 vs. 129 pg/ml, p less than 0.02) at 16 weeks. Thus, although sufficient antibody titers were developed in rats to sequester 76% of the free circulating glucagon from both pancreatic and gut sources, food intakes and body weight gains were decreased, likely as a consequence of an over-compensatory increase in total glucagon concentrations.

Animals↗
PubMed1984

Feeding behavior responses of Zucker rats to naloxone.

The effects of naloxone on feeding patterns were studied in both obese and lean Zucker rats during both light and dark phases of the diurnal cycle. Eight female obese (471 +/- 9 g) and lean (225 +/- 6 g) Zucker rats were trained to bar press for food. They were administered 0, 0.5, 1.0 or 2.0 mg/kg naloxone at the initiation of the light or dark phase of the diurnal cycle and feeding behavior was recorded for the subsequent 12 hr using an automated real-time data collection system. First meal size and duration were decreased and first postmeal interval was increased by naloxone and responses did not vary with phenotype or phase of the diurnal cycle. Naloxone decreased food intake during the 12-hr period by decreasing average meal size but meal frequency was not affected. Overall, the feeding behavior responses of obese rats to naloxone were greater than those of lean rats, supporting the hypothesis of an association between opioid peptides and obesity. Opioid involvement in diurnal control of food intake is also supported by the greater responses generally demonstrated in the light compared with dark phases.

Animals↗
PubMed1984

Increased sensitivity of Zucker obese rats to naloxone is present at weaning.

Increased pituitary and plasma concentrations of opioid peptides in genetically obese rodents may be a cause or consequence of obesity. It has been shown that food intake is decreased more in adult genetically obese rats and mice than lean rats and mice by administration of naloxone, an opiate antagonist. Evidence for an opiate-mediated component in the development of rather than the consequence of obesity would be provided if young, not yet obese, genetically obese rats were more sensitive than lean rats to naloxone. In the present experiment two groups of male and female obese and lean Zucker rats, fasted for 2 hr before the onset of the dark portion of the 12-hr light-dark cycle, were administered 0.125 to 0.5 mg/kg naloxone or 0.5 to 2.0 mg/kg naloxone subcutaneously and 30- and 60-min food intakes were measured. In the group administered the lower doses of naloxone, obese rats of the three ages tested responded more than the lean rats after 30 min (70 vs. 79% of control, p less than 0.02). However, increased sensitivity occurred during the 0-60 min period in rats 4-5 weeks old and 0-30 min period in rats 8-9 and 12-13 weeks old. In the second group tested with the higher doses, the obese responded less than the lean rats (73 vs. 66% of control, p less than 0.05) and there was no difference in response after 0-60 min (66 vs. 61% of control, NS). Thus, increased sensitivity to threshold doses of naloxone occurs before the development of substantial obesity and therefore opiate peptides may play a causal role in obesity.

Aging↗
PubMed1984

Decreased pancreatic CCK receptor binding and CCK-stimulated amylase release in Zucker obese rats.

In Zucker obese rats the response to the effects of CCK on food intake and pancreatic exocrine function are decreased. However, it is unknown whether the decreased responsiveness is due to decreased receptor number and/or sensitivity or abnormal circulating concentrations of CCK. In these experiments percent total binding of 125I-CCK-33 to pancreatic acini from obese rats was one-half that in lean rats when data was expressed on a per microgram DNA basis (19.6 +/- 5.1 vs. 47.4 +/- 11.4, p less than 0.01). In a second experiment while the maximally effective dose of CCK for stimulating amylase secretion from dispersed pancreatic acini was similar in obese and lean rats (10(-10) M), less amylase was secreted in obese rats across the dose range tested (p less than 0.001). In contrast, carbachol had similar potency and efficacy in stimulating amylase release from obese and lean pancreatic acini. The increase of pancreas size by use of a trypsin inhibitor was greater in lean than obese rats (p less than 0.03). In addition, stimulation of amylase release by CCK from obese trypsin inhibitor-treated compared with control obese rats was greater than that from lean trypsin inhibitor-treated compared with control lean rats (p less than 0.002). However, overall, stimulation of amylase secretion by CCK was only 36% of control (p less than 0.001) and by carbachol was only 20% of control (p less than 0.001). Thus, increased size by increased cell number was associated with decreased response per cell.(ABSTRACT TRUNCATED AT 250 WORDS)

Amylases↗
PubMed1983

Trypsin inhibitor effects on food intake and weight gain in Zucker rats.

Decreased body weight and increased pancreas weight which occur in rats fed raw soybeans are thought to be due to the presence of trypsin inhibitors in the soybeans (SBTI). Since trypsin is postulated to be a negative feedback signal for cholecystokinin (CCK) secretion, SBTI may have these effects by increasing secretion of CCK. CCK is a putative satiety signal; thus, increased secretion of CCK could decrease food intake, and, if maintained over a period of time, body weight. In these experiments the effects of a trypsin inhibitor [N,N-dimethyl-carbamoyl 4-(4-guanidino-benzylyloxy)-phenyl acetate methane-sulfate (DGPM)]on feeding pattern were investigated in Zucker obese and lean rats. Administration of 25-200 mg/kg DGPM to 6-hr fasted rats decreased daily food intake by dose-dependently decreasing average meal size in both obese and lean rats, but the response was greater in obese rats. Administration of 100 mg/kg DGPM twice daily for 7 days decreased food intake and body weight in obese but not lean rats. Thus, these results suggest that decreased body weight associated with SBTI is due to decreased food intake partly as a result of increased secretion of the putative satiety peptide CCK.

Animals↗
PubMed1983

Nalmefene decreases meal size, food and water intake and weight gain in Zucker rats.

Opioids are proposed to play a role in the control of food intake since administration of opioids increase food intake while administration of opioid antagonists decrease food intake. In these experiments responses to a new opioid antagonist, nalmefene, were measured in Zucker obese and lean rats. In obese male rats 1 mg/kg nalmefene decreased the size of the first meal after a 10-hr fast and decreased 14-hr food intake, indicating nalmefene is relatively long-acting. Administration of 1 mg/kg nalmefene daily for 7 days decreased average meal size and daily food intake and increased meal frequency; feeding responses on day 7 were similar to those on day 1, suggesting a lack of development of tolerance. Food and water intake and weight gain during a 3-week treatment period were decreased more in lean rats by low doses of nalmefene (up to 0.25 mg/kg) and more in obese rats by higher doses of nalmefene (0.50 mg/kg). These responses to a new opioid antagonist further support a possible role for opioids in the control of food intake.

Animals↗
PubMed1983

Hormones and feed intake.

During the several decades that hormones have been considered for roles in the control of feeding, certain ones have gained special attention, although the role assigned to any one hormone has varied from time to time. Three classes of hormones have been considered in this review: gastrointestinal, brain, and pancreatic. Of these classes, two have obtained the most compelling evidence for a physiological role in the control of feeding. CCK, an intestinal and brain hormone, appears to be involved in satiety. Glucagon of pancreatic origin appears also to play an important role in satiety. These hormones, when sequestered by a specific antibody, cause a delay in satiety and thus increase food intake. Insulin, another pancreatic hormone, has been considered for several roles in the control of feeding. Recently, attention has been given to the possibility that insulin of the CSF provides an integrated link between the metabolic state of the adipose tissue and the brain structures concerned with the control of feeding. Thus, insulin may be a primary hormone involved in the maintenance of energy balance or of body-weight. Finally, brain opiate peptides, e.g. dynorphin, are very likely involved in the transmission of information concerned with the interaction of feeding and maintenance of energy balance. Clearly, hormones play primary roles in the control of feeding behaviour and the regulation of energy balance, but much remains to be done to establish their specific actions or components of the associated physiological systems.

Animals↗
PubMed1983

Hyperphagia during lactation: satiety response to CCK and growth of the pancreas.

Cholecystokinin (CCK) secreted from the duodenum during feeding has been shown to elicit satiety and stimulate growth of the pancreas in addition to affecting gastrointestinal function. In previous experiments hyperphagic Zucker obese rats were less sensitive to the effects of CCK on satiety and had a smaller pancreas than normal-weight rats. In the present experiments with hyperphagic lactating Zucker rats, the food intake response to exogenously administered CCK and the size and composition of the pancreas were measured. Food intakes after a 2-h fast were not decreased by 4.0 or 8.0 micrograms/kg CCK-8 during wk 1, 2, or 3 of lactation. However, in the same rats 2 wk after pups were weaned, 4.0 and 8.0 micrograms/kg CCK-8 decreased food intake 32% (2.1 +/- 0.4 vs. 3.1 +/- 0.3 g, paired t = 2.33, P less than 0.03) and 52% (1.5 +/- 0.2 vs. 3.1 +/- 0.5 g, paired t = 3.48, P less than 0.006). On day 18 of lactation, pancreas weight was increased 41% (1.38 +/- 0.05 vs. 0.98 +/- 0.02 g, paired t = 2.68, P less than 0.02) and contents of DNA, RNA, and protein were increased 57, 57, and 73%, respectively. Thus, hyperphagia in lactating female rats was associated with 1) decreased sensitivity to the satiety effect of CCK similar to that in hyperphagic obese rats and 2) hypertrophy of the pancreas in contrast to decreased pancreas size in obese rats.

Animals↗